extranodal nasal NK/T cell lymphoma
extranodal nasal NK/T cell lymphoma
Explore linked clinical trials. Standard reference: MONDO:001947211 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type | Lymphoma, Extranodal NK-T-Cell, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, extranodal nasal NK/T cell lymphoma, lymphoma, neoplasm | Active, not recruiting | Phase 2 | 2026-09-24 | NCT04414163 | |
| Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma | Disease Attributes, Lymphoma, Extranodal NK-T-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, T-cell non-Hodgkin lymphoma, extranodal nasal NK/T cell lymphoma, lymphoma, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-06-18 | NCT07502768 | |
| Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Lymphadenopathy, Lymphoma, Extranodal NK-T-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, T-cell non-Hodgkin lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, diffuse large B-cell lymphoma, enteropathy-associated T-cell lymphoma, extranodal nasal NK/T cell lymphoma, hematologic disorder, hepatosplenic T-cell lymphoma, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm, peripheral T-cell lymphoma, not otherwise specified, primary cutaneous T-cell non-Hodgkin lymphoma, primary cutaneous anaplastic large cell lymphoma, primary mediastinal large B-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma | Active, not recruiting | Not applicable | 2026-06-16 | NCT01787409 | |
| Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, T-cell non-Hodgkin lymphoma, extranodal nasal NK/T cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm | Not yet recruiting | Phase 1 / Phase 2 | 2026-05-29 | NCT07615283 | |
| A Registry for People With T-cell Lymphoma | ALK-negative anaplastic large cell lymphoma, ALK-positive anaplastic large cell lymphoma, Hemic and Lymphatic Diseases, Leukemia, Large Granular Lymphocytic, Lymphadenopathy, Lymphoma, Extranodal NK-T-Cell, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Sezary syndrome, T-cell leukemia, T-cell non-Hodgkin lymphoma, T-cell prolymphocytic leukemia, adult T-cell leukemia/lymphoma, aggressive NK-cell leukemia, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, breast implant-associated anaplastic large cell lymphoma, enteropathy-associated T-cell lymphoma, extranodal nasal NK/T cell lymphoma, hematologic disorder, hepatosplenic T-cell lymphoma, hydroa vacciniforme-like lymphoma, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, monomorphic epitheliotropic intestinal T-cell lymphoma, mycosis fungoides, neoplasm, peripheral T-cell lymphoma, not otherwise specified, primary cutaneous T-cell lymphoma, primary cutaneous T-cell non-Hodgkin lymphoma, primary cutaneous anaplastic large cell lymphoma, prolymphocytic leukemia, subcutaneous panniculitis-like T-cell lymphoma | Recruiting | Not stated | 2026-05-20 | NCT05978141 | |
| A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma | extranodal nasal NK/T cell lymphoma | Not yet recruiting | Phase 2 | 2026-05-08 | NCT07574528 | |
| Circulating Tumor DNA in Peripheral T-cell Lymphomas | Hemic and Lymphatic Diseases, Lymphoma, Extranodal NK-T-Cell, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, extranodal nasal NK/T cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm | Active, not recruiting | Not stated | 2026-05-01 | NCT06362148 | |
| Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma | Hemic and Lymphatic Diseases, Lymphoma, Extranodal NK-T-Cell, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, extranodal nasal NK/T cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm | Recruiting | Early phase 1 | 2025-12-02 | NCT07162012 | |
| "Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL | extranodal nasal NK/T cell lymphoma | Recruiting | Phase 1 / Phase 2 | 2025-07-14 | NCT06559553 | |
| PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma | Lymphoma, Extranodal NK-T-Cell, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, extranodal nasal NK/T cell lymphoma, lymphoma, neoplasm | Recruiting | Not applicable | 2024-10-26 | NCT05662540 | |
| Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma | Lymphoma, Extranodal NK-T-Cell, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, extranodal nasal NK/T cell lymphoma, lymphoma, neoplasm | Recruiting | Phase 2 | 2023-04-27 | NCT05833893 |